Argollo M¹, Gilardi D², Peyrin-Biroulet C³, Chabot JF³, Peyrin-Biroulet L⁴, Danese S⁵. Lancet Gastroenterol Hepatol. 2019 Jun 3. pii: S2468-1253(19)30173-6. doi: 10.1016/S2468-1253(19)30173-6. [Epub ahead of print]

Author information

1 IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Centre, Milan, Italy; Universidade Federal de São Paulo, São Paulo, Brazil.

2 IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Centre, Milan, Italy.

3 Department of Pneumology, Nancy University Hospital, Lorraine University, Nancy, France.

4 Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Nancy, France.

5 IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Centre, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy. Electronic address: sdanese@hotmail.com.

Abstract

Inflammatory bowel disease (IBD) is a chronic systemic inflammatory condition. Previously, the focus has been on extraintestinal manifestations of IBD, including arthritis, psoriasis, and uveitis. Although comorbidities have long been the subject of intensive research in other chronic inflammatory diseases such as rheumatoid arthritis, the concept of comorbidities is only beginning to emerge in IBD. Several comorbid conditions have been proposed to be related to IBD, including cardiovascular disease, neuropsychological disorders, and metabolic syndrome. Recognition of these conditions and their treatment could lead to better management of IBD. This Review aims to explore current knowledge regarding classic and emerging comorbidities related to IBD.